Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 8/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 5/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 4/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL4159384 | 0.89 | PIM1 (0.36) | PIM1PIM3PIM2EGFRHTR1D | |
| SCHEMBL4174413 | 0.85 | PIM1 (0.41) | PIM1PIM3PIM2HTR1DHTR1A | |
| SCHEMBL4160215 | 0.84 | AURKA (0.39) | — | |
| SCHEMBL3249166 | 0.81 | PIM1 (0.40) | PIM1PIM3PIM2 | |
| SCHEMBL4159498 | 0.80 | PDPK1 (0.39) | — | |
| Formic Acid SCHEMBL3249581 | 0.79 | JAK3 (0.36) | PIM1PIM3PIM2 | |
| SCHEMBL13928213 | 0.79 | JAK2 (0.38) | PIM1PIM3PIM2 | |
| SCHEMBL4157705 | 0.74 | HPGD (0.41) | PIM1PIM3PIM2 | |
| Formic Acid SCHEMBL4160207 | 0.73 | AURKA (0.41) | — | |
| Propionic Acid SCHEMBL4159389 | 0.73 | PIM1 (0.37) | PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | PIM1 279/4885PIM3 337/4885PIM2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.